Abstract
bradykinesia, impaired balance and freezing of gait. 1 However, PD is also associated with many non-motor symptoms, such as cognitive impairment, and abnormalities in the function of the gut, which contribute to overall morbidity of the disease. 1, 3 Unfortunately, despite the scientific advances in our knowledge of disease pathology, there is no cure for PD, only relief from its symptoms. Current therapeutic applications to treat PD target pharmacological replacement of striatal dopamine (ie, Levodopa), coupled with non-dopaminergic drugs to attenuate both motor and non-motor symptoms.
Additionally, deep brain stimulation has also been shown to provide therapeutic relief of symptoms. 1, 3 Interestingly, an enriched environment has also exhibited potential for reducing oxidative damage and olfactory dysfunction in PD mice. 4 Studies in stem cell-based regenerative medicine, which also attempt to exogenously replace dopamine or stimulate endogenous host brain repair, 5, 6 represents efforts towards disease-modifying outcomes as well.
Cord blood plasma (CBP), which can be readily obtained from human umbilical cord blood (hUCB) during routine cell isolation, has mainly been considered a waste product. The potential trophic effects provided by CBP have been shown through culture supplementation of hUCB-derived mesenchymal stem cells (MSCs), 7 hUCB-derived T-lymphocytes, 8 human dental cells 9 or human endothelial colony-forming cells 10 in vitro. Indeed, CBP may have underlying potential as a source of treatment for neurological diseases,
given that hUCB cell grafts migrate to injury sites 11 and emit growth factors that ameliorate ischaemia, 12 hUCB mononuclear cells increase neurogenesis in aged rats, 13 and neural cells derived from human placentas attenuate neuroinflammation and confer neuroprotection in PD rats. 14 Additionally, in vivo studies determining the therapeutic potential of CBP in rats modelling acute ischemic stroke have been investigated with results showing enhancement of neurogenesis and reduced inflammation providing significant functional recovery post-stroke. 15 Moreover, α-secretase extracted from CBP has also demonstrated the ability to improve cognitive deficits and amyloid plaque formation in Alzheimer's disease mouse models. 16 Several studies have also investigated the composition of CBP with reports finding high amounts of various growth factors, along with a unique cytokine profile consisting of a low concentration of various pro-inflammatory cytokines. 8, 17, 18 Although CBP can have beneficial effects on cells in culture, the ability of CBP to elicit therapeutic benefits in models of neurodegenerative disorders must be determined before developing clinically relevant CBP-based therapies.
Since inflammation has been connected to the progressive exacerbation of neurological diseases 19 and the inflammatory gut microbiome has recently been linked to a number of neurological disorders, [20] [21] [22] [23] [24] including Parkinson's, [25] [26] [27] this study was designed to analyse the gut for MPTP-induced PD-related dysfunction and to determine the therapeutic potential CBP at reducing the gut inflammation that may be present in this particular model. Findings from this study may aid in providing further support to the notion that a non-dopaminergic and non-CNS organ may contribute to PD pathology. 21, 23, 28 Additionally it is of specific interest to determine if intravenous (iv) delivery of CBP could provide therapeutic benefit in both gut and brain tissues. This would provide valuable translational guidance for the development of a stand-alone CBP therapeutic or quite possibly a combined CBP with stem cell therapy in targeting the gut microbiome for PD treatment.
The aim of this study was to determine if CBP alone is beneficial in reducing PD-associated pathology in the brain and gut induced by intraperitoneal (ip) administration of an MPTP insult. Since the full efficacy of a CBP-based therapy might not be ascertainable using a single injection, multiple administrations of CBP were provided over a 14 day period. To assess the efficacy of this treatment plan the motor, neurological and non-motor related pathologies of PD assessed at baseline (day 0) and at days 1, 3, 7 and 14 after MPTP administration. Tissue pathology was examined using immunohistochemistry to help determine the extent of the MPTP-induced nigral lesion and resultant inflammation in both the brain and intestinal tissues. Finally the populations of several inflammatory gut-related microbiota were assayed to determine the relative inflammatory state of the gut microbiome. These study results provide insight into the potential of a CBP therapy for the treatment of neurodegenerative diseases.
| MATERIAL S AND ME THODS

| hUCB plasma
Frozen units of hUCB plasma (CBP) were provided by Saneron CCEL Therapeutics, Inc The CBP was aseptically isolated using the Sepax 2 fully automated cell processing system (Biosafe America Inc, Houston, TX), and tested for sterility using the BacT/ALERT microbial detection system (bioMérieux, Durham, NC) prior to freezing.
| Animals
All experimental procedures were approved by the University of South Florida Institutional Animal Care and Use Committee (IACUC). Male Sprague-Dawley rats (8 weeks old, n = 30) were housed under normal conditions (20°C, 50% relative humidity, and a 12-hour light/dark cycle). All necessary precautions were taken to reduce pain and suffering of animals throughout the study. Animals were closely checked daily throughout the 2 week study period. All studies were performed by personnel blinded to the treatment condition. 
| Preparation of the animal model
| Behavioural testing
Behavioural tests for the observation of parkinsonian-like motor and non-motor deficits were administered at intervals prior to, 7 days post and 14 days post MPTP lesion. Standard behavioural testing included rotarod, forelimb akinesia and paw grasp were performed to observe generation of the classical motor-function deficits and neurological dysfunction seen in PD. Distal colonic propulsion and gastric emptying studies (described below) were performed to observe changes in the gut associated non-motor symptoms of PD.
| Distal colonic propulsion
To measure colonic propulsion on day 7 and day 14 after MPTP administration, a single 5-mm-diameter glass bead was inserted into the distal colon to a distance of about 2 cm from the anus of each rat. After bead insertion, the rats were replaced individually without food and water in their home cages. Thereafter the animals underwent observation to ensure they showed normal behaviour, and the amount of time necessary for excretion of the glass bead was measured. The time required for expulsion of the glass bead, called mean expulsion time (MET), was determined (to the nearest 1.0 second) for each rat and the inhibition of colonic propulsion measured as the increase in MET versus control rats. The higher the MET value, the stronger the inhibition of colonic propulsion.
| Gastric emptying
At the study termination day, all groups were provided an oral solu- 
| Tissue collection
Under deep anesthesia, the rats were sacrificed at 14 days after MPTP insult. Animals were perfused transcardially with approximately 200 mL of ice cold PBS followed by 200 mL of 4% paraformaldehyde in PBS. The intestines and brains of these animals were removed and post-fixed in the same fixative for 24 hours at 4°C.
These tissues were then transferred to 30% sucrose in PB for at least 16 hours prior to tissue sectioning. Coronal sections were cut (40 µm) using a cryostat, collected and stored in a cryoprotectant solution at −20°C.
| Immunohistochemistry
Staining tyrosine hydroxylase (TH) conducted on every sixth coronal section throughout the entire substantia nigra (SN). In 
| Immunofluorescence
Immunofluorescent staining for the inflammatory markers of major histocompatibility complex (MHCII) and tumor necrosis factor alpha (TNF-α) were conducted on every sixth coronal section throughout the entire SN. In all animals, sections were anatomically matched. 
| Gut microbiome analysis
The presence and concentration of specific inflammatory, potentially harmful, microbiotic species residing within the gut was determined. Fluorescent in-situ hybridization (FISH) analysis was used to identify the specific microbiota within the feces of the rats in this study. Fecal matter (1 g) collected during
tissue processing was suspended in 2 mL of PBS and homogenized by repeated pipetting with a 1mL micropipettor and mixed using a vortex. Four per cent paraformaldehyde (6 mL) was added to the homogenized feces and stored overnight at 
| Statistical analysis
Behavioural data, image analyses and microbiome data are presented as mean ± SD Statistical analysis was performed using Statview (Abacus Corporation). The results for the assays in this study were analysed using one-way ANOVA with Bonferroni post-hoc analysis.
A value of P < 0.05 was considered significant.
| RE SULTS
| Effects of CBP on motor, neurological and gastrointestinal function in PD animals
The efficacy of multiple injections CBP was investigated in a gut-in- 
| Effects of CBP on the histopathology of PD brain and gut
Histopathological staining of brain tissues was performed to document changes in dopaminergic neuron populations in the SNpc. Additionally, Figure 3A ). Image analysis of this TH staining revealed that animals that received CBP vs vehicle controls showed a significant (P < 0.01) reduction in dopaminergic depletion ( Figure 3B ).
Additionally, the presence of immune cells populations (MHCII) in the SNpc was significantly (P < 0.01) reduced in response to CBP treatment ( Figure 3C) , with the staining for TNF-α also showing significant (P < 0.01) reductions in the expression of this pro-inflammatory cytokine in MPTP lesioned animals that received CBP vs vehicle controls ( Figure 2D ). These effects were mirrored in the gut tissue of these animals with a significant (P < 0.01) reduction of both MHCII positive immune cells and TNF-α cytokine production in animals treated with CBP vs vehicle controls ( Figure 3E and 3, respectively) .
F I G U R E 3 Effect of cord blood plasma (CBP) on the histopathology of Parkinson's in the brain and gut. On day 14 following induction of Parkinson's disease pathology with intraperitoneal injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) the therapeutic effect of CBP treatment was observed in brain and gut tissues. MPTP lesioned rats treated with CBP noted significant reduction in THcell depletion in the substantia nigra (A,B) paired with a significantly decreased inflammatory response as evidenced by decreased major histocompatibility complex (MHCII) and tumour necrosis factor alpha (TNF-α) intensity in the brain of CBP-treated animals (C,D). Similarly, the inflammation of the gut found to be significantly reduced through decreased MHCII (E,F) and TNF-α (G,H) intensity present in the intestinal villi of animals treated with CBP. These findings parallel the trend of behavioural improvements in these animals that received intravascular injections of plasma. *,&: P < 0.05, **: P < 0.01 Scale bar in A is 50 µm. Scale bar in C, E, G is 100 µm
| Effects of CBP on populations of inflammatory microbiota in PD animals
The prevalence of several potentially harmful microbiota species were investigated using FISH. While the levels of LAB158, BAC303, and EREC482 were found to be elevated at day 14 following MPTP lesion in lesioned animals treated with vehicle. Significant (P < 0.05) reductions in the amount of LAB158 and BAC 303 were observed in the gut of MPTP animals that were given multiple injections of CBP vs vehicle control ( Figure 4A, 4) . While the population of EREC482 also decreased in response to CBP treatment this observation was not found to carry significance ( Figure 4C ).
| D ISCUSS I ON
In this study, the potential of CBP as a viable therapeutic agent for both motor and non-motor symptoms in the gut-induced MPTP rat model of PD was evaluated. Tests of motor function, neurological behaviour and gastric motility were employed to investigate the therapeutic efficacy of CBP. The ability of CBP to reduce nigral dopaminergic cell loss, while preventing both immune cell activation and pro-inflammatory cytokine production was also determined. The effect of CBP on the elevated levels of inflammation-associated microbiota in the gut was examined and compared to levels observed in the vehicle group. The major study find- In the development of treatments for PD, dopaminergic cell replacement has been widely considered as the most straightforward and appealing approach. The first transplantation of fetal derived dopaminergic cells into PD patients resulted in not only survival of the transplant but also integration into the host dopaminergic network. 29, 30 Unfortunately only modest improvements were observed with decreasing positive effects seen over the long-term in transplanted PD patients. 31, 32 Additionally, a small group of patients that received fetal dopaminergic transplants displayed worsening dyskensias. 33 While the strategy of conventional dopaminergic cell replacement is still being pursued, 34 other effects relating simply to the transplantation of stem cells appears to produce therapeutic benefit both peripherally and centrally. These secondary effects, previously examined in animal models of PD, 35, 36 F I G U R E 4 Effect of cord blood plasma (CBP) on populations of inflammatory microbiota. In tandem with the behavioural and histological assays, we also assayed the gut for three biomes associated with inflammation. The levels of (A) LAB158, (B) BAC303 and (C) EREC482 were detected using a fluorescent in-situ hybridization assay, and found to be elevated at day 14 following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion in lesioned animals treated with vehicle. These levels were reduced in lesioned animals that received CBP, with significant reductions found for both LAB158 and BAC303, suggesting that the plasma exerted anti-inflammatory effects in the gut that may have contributed to the observed functional recovery. *,&:
This study offers many novel observations that should lay the foundation for future mechanism and optimization studies of CBP. gation, such by-stander effects were previously examined in PD rats 35, 42 and primates. 36 The extent to which the stem cell-secreted therapeutic substances reach the striatum and substantia nigra following intravascular transplantation will be of valuable translational and optimization guidance in advancing CBP and stem cell-based therapy, 36, 44 especially for targeting the gut microbiome in PD treatment.
In conclusion our study results show that multiple administrations of CBP in a MPTP gut-induced rat model of PD effectively reduced motor and non-motor dysfunction, which were accompanied by suppression of the pro-inflammatory cytokine production in both the brain and gut. A decrease in prevalence of several harmful microbiotic species found in the gut of these animals was also observed. While additional motor and neurological testing, such as paw grasp testing and forelimb akinesia, were primarily used in this study to validate the generation of PD-like motor dysfunction in an intraperitoneally injected MPTP rat model, some trends of amelioration of motor deficits resulting from multiple injections of CBP were observed (data not shown).
Interestingly, the therapeutic effects of iv CBP administration appear not limited to the brain function, but attenuate non-motor symptoms (gut motility) as well. These findings indicate that additional studies investigating both a longer therapeutic time period and potentially larger doses of CBP should be investigated as these modifications may improve therapeutic efficacy. Additionally, that CBP robustly restored the non-motor gut functions in PD suggests that monitoring of specific physiological indices such as body weight and food consumption may be essential in validating these GI effects. Optimization of CBP timing of treatment, doses and routes of delivery as stand alone or in combination with cord blood stem cells may provide the most effective and safe cell-based regenerative medicine necessary to sequester the inflammation-plagued brain degeneration and gut microbiome that plagues PD and various neurodegenerative diseases.
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